Advertisement

Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

      In their article, “Development of Tachyphylaxis Among Patients Taking HMG CoA Reductase Inhibitors,” Cromwell and Ziajka
      • Cromwell W.C.
      • Ziajka P.E.
      Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
      claim that treatment with atorvastatin for >200 days is associated with a lessening of low-density lipoprotein (LDL) cholesterol-lowering efficacy. I have a number of concerns over the validity of this observation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cromwell W.C.
        • Ziajka P.E.
        Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
        Am J Cardiol. 2000; 86: 1123-1127
        • Jones P.
        • Kafonek S.
        • Laurora I.
        • Hunninghake D.
        • CURVES investigators
        Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
        Am J Cardiol. 1998; 81: 582-587
        • Pitt B.
        • Waters D.
        • Brown W.V.
        • van Boven A.J.
        • Schwartz L.
        • Title L.M.
        • Eisenberg D.
        • Shurzinske L.
        • McCormick L.
        • Atorvastatin versus Revascularization Treatment Investigators
        Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
        N Engl J Med. 1999; 341: 70-76
        • Brown A.S.
        • Bakker-Arkema R.G.
        • Yellen L.
        • Henley Jr, R.W.
        • Guthrie R.
        • Campbell C.F.
        • Koren M.
        • Woo W.
        • McLain R.
        • Black D.M.
        Treating patients with documented atherosclerosis to National Cholesterol Education Program–recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
        J Am Coll Cardiol. 1998; 32: 665-672
        • Heinonen T.M.
        • Stein E.
        • Weiss S.R.
        • McKenney J.M.
        • Davidson M.
        • Shurzinske L.
        • Black D.M.
        The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor.
        Clin Ther. 1996; 18: 853-863

      Linked Article